Veracyte, Inc. Files 8-K for Financials
Ticker: VCYT · Form: 8-K · Filed: May 7, 2024 · CIK: 1384101
| Field | Detail |
|---|---|
| Company | Veracyte, Inc. (VCYT) |
| Form Type | 8-K |
| Filed Date | May 7, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, sec-filing
Related Tickers: VCYT
TL;DR
VCYT filed an 8-K for financial updates - check for details.
AI Summary
Veracyte, Inc. filed an 8-K on May 7, 2024, to report on its results of operations and financial condition, as well as to file financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text, but serves as a notification of these items.
Why It Matters
This filing indicates Veracyte is providing updates on its financial performance and condition to the SEC, which is important for investors to monitor the company's health.
Risk Assessment
Risk Level: low — This is a routine filing to report financial information and does not inherently present new risks.
Key Players & Entities
- VERACYTE, INC. (company) — Registrant
- CALDEROME INC (company) — Former company name
FAQ
What specific financial results are being reported by Veracyte, Inc. in this 8-K?
The provided text of the 8-K filing does not specify the exact financial results being reported, only that the filing pertains to 'Results of Operations and Financial Condition'.
When was this 8-K filing submitted to the SEC?
The filing was submitted on May 7, 2024.
What is Veracyte, Inc.'s principal executive office address?
Veracyte, Inc.'s principal executive offices are located at 6000 Shoreline Court, Suite 300, South San Francisco, California 94080.
What is Veracyte, Inc.'s IRS Employer Identification Number?
Veracyte, Inc.'s IRS Employer Identification Number is 20-5455398.
What is the SIC code for Veracyte, Inc.?
Veracyte, Inc.'s Standard Industrial Classification (SIC) code is 8071, which corresponds to SERVICES-MEDICAL LABORATORIES.
Filing Stats: 507 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-05-07 16:10:17
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share VCYT The Nasdaq Stock Market
Filing Documents
- vcyt-20240507.htm (8-K) — 28KB
- vcyt-05x07x20248xkearnings.htm (EX-99.1) — 220KB
- vcytlogoa.gif (GRAPHIC) — 6KB
- 0001384101-24-000064.txt ( ) — 397KB
- vcyt-20240507.xsd (EX-101.SCH) — 2KB
- vcyt-20240507_lab.xml (EX-101.LAB) — 22KB
- vcyt-20240507_pre.xml (EX-101.PRE) — 13KB
- vcyt-20240507_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On May 7, 2024, Veracyte, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024. The full text of the press release is furnished as Exhibit 99.1 to this report. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release issued by Veracyte, Inc. dated May 7, 2024 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: May 7, 2024 VERACYTE, INC. By: /s/ Rebecca Chambers Name: Rebecca Chambers Title: Chief Financial Officer Principal Financial Officer